ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urologic Neoplasms
Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
30 Active assets in the Urologic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN Region Skane | Phase 4 | BB |
Docetaxel Sandy Srinivas | Phase 3 | BB |
Abiraterone Acetate Eli Lilly and Company | Phase 3 | B |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eli Lilly and Company | Phase 3 | B |
View all 50 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →